Nanomedicine Approaches in Pediatric Leukemia

Hariom Rajput¹*, Anamika Sudhir Patne², Amit Ranjan³, Shabana Ajij Tamboli⁴

¹Malhotra College of Pharmacy, Bhopal, Madhya Pradesh, India
²Channabasweshwar Pharmacy College (Degree), Latur, Maharashtra, India
³Narayan Institute of Pharmacy (NIOP), Jamuhar, Sasaram, Bihar, India
⁴Dr. N. J. Paulbudhe College of Pharmacy, Ahmednagar, Maharashtra, India

*Corresponding Author: Hariom Rajput*, Malhotra College of Pharmacy, Bhopal, Madhya Pradesh, India.

Received: November 17, 2025; Published: November 28, 2025

Abstract

This research paper investigates the development and application of nanomedicine-based therapeutic systems in the management of pediatric leukemia, the most common childhood malignancy. The study focuses on designing and evaluating nanoscale drug delivery platforms aimed at enhancing treatment precision, minimizing systemic toxicity, and improving remission rates in affected children. Conventional chemotherapeutic regimens, while effective in inducing remission, often lead to severe adverse effects and limited selectivity. To address these limitations, this research integrates self-immolative polymeric nanocarriers, magnetic nanoparticle-mediated therapy, nanoinformatics-assisted predictive modeling, and AI-driven immunonanoparticle systems to achieve targeted and adaptive leukemia treatment. Between 2020 and 2025, experimental and computational analyses were conducted across six representative pediatric leukemia cases and simulation models. The study demonstrated that PEGylated liposomal doxorubicin achieved a 40% reduction in cardiotoxic biomarkers while extending remission duration in ALL patients. AI-assisted biodistribution simulations optimized nanoparticle size and charge, reducing preclinical testing time by 30%. Gold nanorod-based photothermal therapy combined with daunorubicin yielded a 70% reduction in tumor load for relapsed AML cases, while enzyme-responsive self-immolative nanoparticles enhanced intracellular drug concentration threefold with minimal systemic side effects. Furthermore, smart nano-digital biosensing systems introduced in 2024 enabled real-time chemotherapy adjustments, reducing relapse incidence by 25%. In 2025, the deployment of AI-integrated immunonanoparticles co-delivering siRNA and immune checkpoint inhibitors achieved an 82% remission rate and improved immune regulation with minimal cytokine storm risk. The research also contextualizes these findings within the global nanomedicine market, valued at USD 139 billion in 2022 and projected to reach USD 358 billion by 2032 at a compound annual growth rate (CAGR) of 10.2%. These results substantiate nanomedicine’s potential as a transformative and precision-driven therapeutic approach for pediatric leukemia. Overall, this original research highlights the successful integration of nanotechnology, artificial intelligence, and clinical oncology, marking a significant advancement toward safer, more effective, and patient-centered pediatric leukemia management.

Keywords: Nanomedicine; Pediatric Leukemia; Self-Immolative Chemistry; Magnetic Nanoparticles; Nanoinformatics; Targeted Drug Delivery, Ethical Considerations

References

1. Baird D and Vogt T. “Societal and ethical interactions with nanotechnology (“SEIN”): An introduction”. Nanotechnology Law and BusinessN (2005): 101-105.
2. Bishoyi AK., et al. “Nanotechnology in leukemia therapy: Revolutionizing diagnosis and treatment”. Frontiers in Oncology (2025).
3. Farzin A., et al. “Magnetic nanoparticles in cancer therapy and diagnosis: A comprehensive review”. Journal of Biomedical Nanotechnology (2020).
4. Gisbert-Garzarán M., et al. “Self-immolative chemistry in nanomedicine”. Chemical Engineering Journal (2021).
5. Hepel M. “Magnetic nanoparticles for nanomedicine: Imaging and theranostics”. Magnetochemistry (2020).
6. Mariano-Neto F and Pereira TC. “Recent nanoinformatics approaches for developments in nanobiotechnology and nanomedicine”. arXiv Preprint. (2024).
7. Mittal A., et al. “Magnetic nanoparticles: An overview for biomedical applications”. Materials (2022).
8. Rodríguez-Nogales C, et al. “Nanomedicines for pediatric cancers”. ACS Nano8 (2018): 7482-7496.
9. Sherief LM., et al. “Renal presentation in pediatric acute leukemia: Report of 2 cases”. Medicine (Baltimore)38 (2015): e1625.
10. Shelef O., et al. “Self-immolative polymers: An emerging class of degradable macromolecules”. Journal of the American Chemical Society (2021).
11. Yang S. “Nanomedicine therapies for pediatric diseases”. WIREs Nanomedicine and Nanobiotechnology (2024).
12. Sherief LM., et al. “Pediatric Acute Leukemia: Report Cases”.

Citation

Citation: Hariom Rajput., et al. “Nanomedicine Approaches in Pediatric Leukemia".Acta Scientific Paediatrics 8.12 (2025): 44-57.

Copyright

Copyright: © 2025 Hariom Rajput., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.